CYP2D6 and breast cancer: The analysis confirmed that individuals with PM phenotypes had an increased risk of breast cancer recurrence and/or mortality associated with reduced CYP2D6 activity, while IM showed modest effects in European populations but larger, likely biased, effects in Asian cohorts.